Puma Biotech (PBYI) Tops Q1 EPS by 89c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Puma Biotechnology (PBYI) PT Lowered to $41 at Cowen
May 10, 2019 6:27 AM EDTCowen analyst Chris Shibutani lowered the price target on Puma Biotechnology (NASDAQ: PBYI) to $41.00 (from $56.00) while maintaining a Market Perform rating.
The analyst comments "1Q19 Nerlynx sales widely missed expectations owing to a mix of factors, some familiar (greater discontinuations), others more discomforting... More
